Taisho Pharmaceutical Holdings Co., Ltd.
4581
Rang in Aktien
#3722
Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise... Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise involved in the comprehensive research, development, production, marketing, and distribution of both non-prescription (OTC) and ethical pharmaceutical products, serving markets in Japan and worldwide. The company's operations are divided into two principal divisions: the Self-Medication Operation Group and the Prescription Pharmaceutical Operation Group. The Self-Medication Group provides a diverse portfolio of consumer health products, including over-the-counter medicines, quasi-pharmaceuticals, food products, and general medical and hygiene items. Prominent brands within this segment include the Lipovitan energy drink series, Pabron cold and sinus remedies, RiUP hair re-growth solutions, Taisho Kampo gastrointestinal treatments, Colac laxatives, Naron and other pain relievers for fever, Preser hemorrhoid treatments, Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic-analgesic relief, Counterpain topical anti-inflammatory products, Vitacilina dermatological treatments, and VICKS cough suppressant throat lozenges and medicated drops. This division also encompasses real estate leasing, facility management, and hotel operations. Conversely, the Prescription Pharmaceutical Group specializes in ethical drugs such as Edirol, an active vitamin D3 agent for osteoporosis; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate for osteoporosis; Lusefi, an agent for type 2 diabetes mellitus; and LOQOA, a transdermal anti-inflammatory analgesic. This segment is also engaged in ongoing drug development, primarily focusing on therapeutic areas like central nervous system disorders, infectious diseases, metabolic conditions, and orthopedic ailments. Additionally, Taisho Pharmaceutical Holdings supplies raw materials for pharmaceutical and quasi-drug manufacturing, alongside offering health foods and skincare products. The company was established in Tokyo, Japan, in 1912, where its headquarters remain.
Aktienkurs
$54.31
Zuletzt synchronisiert: 2024-04-08
Marktkapitalisierung
$4.45B
Veränderung (1 Tag)
-4.14%
Veränderung (1 Jahr)
0.00%
Land
JP
Handel Taisho Pharmaceutical Holdings Co., Ltd. (4581)
Kategorie
Healthcare
Operative Marge für Taisho Pharmaceutical Holdings Co., Ltd. (4581)
Operative Marge zum 2026 TTM: 0.00%
Laut den neuesten Finanzberichten und dem Aktienkurs von Taisho Pharmaceutical Holdings Co., Ltd. beträgt die aktuelle operative Marge (TTM) 0.00%. Am Ende des Jahres 2026 lag die operative Marge bei 0.00%.
Historie der operativen Marge von Taisho Pharmaceutical Holdings Co., Ltd. von 2006 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2023 | 7.64% | 90.52% |
| 2022 | 4.01% | -43.36% |
| 2021 | 7.08% | -4.71% |
| 2020 | 7.43% | -37.77% |
| 2019 | 11.94% | -9.55% |
| 2018 | 13.20% | 15.49% |
| 2017 | 11.43% | 14.76% |
| 2016 | 9.96% | -9.54% |
| 2015 | 11.01% | -21.80% |
| 2014 | 14.08% | 13.64% |
| 2013 | 12.39% | -12.50% |
| 2012 | 14.16% | -13.71% |
| 2011 | 16.41% | 22.28% |
| 2010 | 13.42% | -9.32% |
| 2009 | 14.80% | -19.30% |
| 2008 | 18.34% | 35.75% |
| 2007 | 13.51% | -37.31% |
| 2006 | 21.55% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 0.00% | - |
DE
|
|
| 0.00% | - |
DE
|
|
| 0.00% | - |
JP
|
|
| 0.00% | - |
CH
|
|
| 22.93% | - |
IN
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.